PCA
AMRX icon

Pallas Capital Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Pallas Capital Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,355
Closed -$130K – 869
2025
Q4 		$130K Buy
+10,355
New +$118K ﹤0.01% 835

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Pallas Capital Advisors's AMRX Position: Q1 2026 in Review

Pallas Capital Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 10,355 shares — an estimated $130K sold.

Pallas Capital Advisors first reported a position in AMRX in Q4 2025 and held it in 1 quarter. The position peaked at $130K in Q4 2025. 317 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Pallas Capital Advisors reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Pallas Capital Advisors sold 10,355 Amneal Pharmaceuticals shares in Q1 2026, an estimated $130K.
  • Pallas Capital Advisors first reported a position in Amneal Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Pallas Capital Advisors's Amneal Pharmaceuticals position peaked at $130K in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.